Switching between antitumour necrosis factor alpha biologic agents - Is patient weight an important consideration?

British Journal of Dermatology

Volumn 160, Issue 5, 2009, Pages 1123-1124

  Downs, A M R ^a  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adalimumab; Etanercept; Infliximab; Psoriasis; Switching

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BIOLOGICAL THERAPY; BODY MASS; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PSORIASIS; RELAPSE; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT;

ANTIBODIES, MONOCLONAL; BODY MASS INDEX; BODY WEIGHT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64849102440     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09063.x     Document Type: Letter

References (4)

1. Pitarch G, Sanchez-Carazo JL, Mahiques L et al. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007 32 : 18 22.
2. Haitz KA, Kalb RE. Infliximab in the treatment of psoraisis in patients previously treated with etanercept. J Am Acad Dermatol 2007 57 : 120 5.
3. Barde C, Thielen AM, Saurat JH. Infliximab then efalizumab, the hit and run approach, does not work. Dermatology 2008 216 : 171 2.
4. Clark L, Lebwohl M. The effect of weight on biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008 58 : 443 6.